Top Markets
Coin of the day
Kazia Therapeutics Limited Kazia Therapeutics Limited

Kazia Therapeutics Limited

KZA
주식 순위 #35840
Kazia Therapeutics Limited is a biotechnology firm specializing in oncology,... Kazia Therapeutics Limited is a biotechnology firm specializing in oncology, committed to developing innovative therapies for cancer. Its flagship product candidate, Paxalisib, is a brain-penetrant small molecule that inhibits the PI3K/Akt/mTor pathway and is currently being investigated as a potential treatment for glioblastoma. Additionally, the company is progressing EVT801, an investigational new drug aimed at combating various types of cancer. Established in 1994 and headquartered in Sydney, Australia, the entity was formerly known as Novogen Limited before adopting the name Kazia Therapeutics Limited in November 2017.
주가
$0.05207079
마지막 동기화: 2023-11-15
시가총액
$3.38M
변동 (1일)
0.13%
변동 (1년)
0.00%
국가
AU
거래 Kazia Therapeutics Limited (KZA)

카테고리

Kazia Therapeutics Limited (KZA)의 EPS
2026 기준 EPS TTM: 0
Kazia Therapeutics Limited의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Kazia Therapeutics Limited의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS